Stay updated with breaking news from Nasdaq Itci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mach 1 Financial Group LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 7,180 shares of the biopharmaceutical company’s stock, valued at approximately $514,000. Several other hedge funds and other institutional investors […]
Mach 1 Financial Group LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,180 shares of the biopharmaceutical company’s stock, valued at approximately $514,000. A number of […]
Several analysts have recently updated their ratings and price targets for Intra-Cellular Therapies (NASDAQ: ITCI): 4/24/2024 – Intra-Cellular Therapies had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock. 4/23/2024 – Intra-Cellular Therapies had its price target raised by analysts at Canaccord Genuity Group Inc. […]
Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 36.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,738 shares of the biopharmaceutical company’s stock after acquiring an additional 4,974 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s […]
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, Benzinga reports. They presently have a $120.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 66.37% from the stock’s […]